<DOC>
	<DOCNO>NCT01624038</DOCNO>
	<brief_summary>The study hypothesis treatment Erythropoietin ( EPO ) combine Human Erythropoietin ( HUO ) therapy result hematologic improvement thalassemia intermedia patient . Second determine whether follow correlate improve hematologic response : A decrease hemolysis , assayed decrease LDH , compare baseline level , baseline Erythropoietin level , baseline hemoglobin level baseline reticulocyte count ( % circulate nucleated erythroblasts/100 WBCs ) . Goal : The aim ass possibility steady increase hemoglobin level thalassemia intermedia patient least 1g/dl baseline level therapy use Hydroxyurea Erythropoietin , growth evaluation , quality life ( QoL ) decline transfusion requirement study period . Also report compare adverse event publish data regard .</brief_summary>
	<brief_title>Therapeutic Effect Safety Combined Hydroxyurea With Recombinant Human Erythropoietin .</brief_title>
	<detailed_description>To determine whether follow correlate improve hematologic response : A decrease hemolysis , assayed decrease LDH , compare baseline level , baseline Erythropoietin level , baseline hemoglobin level baseline reticulocyte count ( % circulate nucleated erythroblasts/100 WBCs ) . To assess possibility steady increase hemoglobin level thalassemia intermedia patient least 1g/dl baseline level therapy use Hydroxyurea Erythropoietin , growth evaluation , quality life ( QoL ) decline transfusion requirement study period . Also report compare adverse event publish data regard . THE following criterion use include patient study : Patients thalassemia intermedia.Diagnosis base genetic mutation , hemoglobin electrophoresis characteristic clinical data presentation . Patients require different transfusion requirement transfusion dependent.Patients baseline hemoglobin less equal 6-8g/dl.Patients normal renal liver function .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients thalassemia intermedia . Diagnosis base genetic mutation , hemoglobin electrophoresis characteristic clinical data presentation . Require different transfusion requirement transfusion dependent . Have baseline hemoglobin less equal 68g/dl . Patients normal renal liver function . Evidence active hepatitis ( ALT &gt; 5 time ULN ) . Evidence renal impairment ( serum creatinine &gt; ULN ) . Patients dependent red blood cell transfusion .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Hydroxyurea</keyword>
	<keyword>Erythropoitin therapy</keyword>
	<keyword>Thalassemia intermedia</keyword>
</DOC>